ID PharmD @BellevueHosp | PGY2 ID @URMCPharmRes | PGY1 @AtlanticHealth | @RutgersU โ20 | Bugs ๐ฆ & drugs ๐ | #TwitteRx | She/Her | Views are my own
New York, USA
Joined September 2020
- Tweets252
- Following349
- Followers355
- Likes1.3K
Ashita Debnath, PharmD, BCIDP retweeted
So honored to see this piece published in @NEJM! Hoping people share this widely to highlight the devastating implications of defunding HIV-related programs and the legacy we all must uphold.
Perspective essay by Ofole Mgbako, MD: Honoring the Legacy of the HIV Epidemic nej.md/4h98PUY
#MedicalEthics #PublicHealth
ALT A quote from a Perspective published in the New England Journal of Medicine reads as follows: "I added his name to my short but running list of patients who have died from AIDS-related complications โ deaths that should not be happening more than 40 years into the epidemic." The Perspective is titled "Honoring the Legacy of the HIV Epidemic" and the author is Ofole Mgbako, M.D. The background color is blue and includes the NEJM logo.
Ashita Debnath, PharmD, BCIDP retweeted
EMBLAVEO: catchy name & innovative antibiotic
Enterobacterales-MBL-AVibactam-aztrEOnam
Aztreonam/avibactam is being developed on the rationale that
โก๏ธAztreonam isn't hydrolyzed by MBL enzymes
โก๏ธAvibactam takes care of
serine ฮฒ-lactamases, eg ESBL/AmpC , co-produced by MBL
Breaking news๐ฅ
US FDA approves EMBLAVEO (aztreonam and avibactam) for complicated intra-abdominal infections (cIAI) in adult patients who have limited or no alternative options #idxposts
Ashita Debnath, PharmD, BCIDP retweeted
The removal of #HIV- and #LGBTQ-related resources from the websites of the @CDCgov and other health agencies is deeply concerning.
Access to this information is crucial for ID and HIV health care professionals.
Our full statement: bit.ly/3PYun9v
Ashita Debnath, PharmD, BCIDP retweeted
๐ฐ Extra! Extra! Read all about the 2024 updates to the IDSA Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Below are highlights from the Notable Updates from 2023 section. For more info: buff.ly/3WdrVyr
#AntimicrobialResistance #IDTwitter
Ashita Debnath, PharmD, BCIDP retweeted
The largest study of Pseudomonas endocarditis to date
๐๏ธ๐ฅ#JAC @Shahnanigans1 @ryankshields
Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis
Combination therapy did not improve clinical outcomes
#IDXposts #IEwiki academic.oup.com/jac/articleโฆ
Ashita Debnath, PharmD, BCIDP retweeted
Is anaerobic coverage necessary for aspiration pneumonia with metronidazole or Augmentin?
NEJM JWatch reports from a large retro study with N ~ 4000
Findings show no added mortality benefit but an increased risk of CDI
journal.chestnet.org/articleโฆ
#IDTwitter #IDXposts
Ashita Debnath, PharmD, BCIDP retweeted
๐ฅ Just published ๐ฅ
@IDSAInfo 2024 Guideline Update on the Risk Assessment, Diagnostic Imaging, and Microbiological Evaluation of Complicated Intra-abdominal Infections in Adults, Children, and Pregnant People #idxposts idsociety.org/practice-guideโฆ
Ashita Debnath, PharmD, BCIDP retweeted
๐๏ธโก๏ธ#JAC
Clinical outcomes in patients infected with ertapenem only resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales #IDXposts #CRE academic.oup.com/jac/articleโฆ
Ashita Debnath, PharmD, BCIDP retweeted
๐ฅBLING III RCT
โก๏ธContinuous vs Intermittent ฮฒ-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis
โญThe observed difference in 90-day mortality did not meet statistical significance in the primary analysis.
โญA clinically important benefit with CI is possible.
Ashita Debnath, PharmD, BCIDP retweeted
This #IDPharmacistsDay remember the "5 Ways Pharmacists can Be Antibiotics Aware!" Visit sidp.org/AMSToolkit to access information on ways to contribute to #AntimicrobialStewardship.
@SIDPharm
Ashita Debnath, PharmD, BCIDP retweeted
๐ฅORACLE๐ฅ @yourICM
@TrubianoJason
A Pilot RCT of Direct Oral Challenge(DOC) vs Routine Care in Low-Risk Penicillin Allergy in Critical Illnes
This study supports the safety & efficacy of DOC in low-risk[PEN -FAST< 3] penicillin allergy in ICU #IDXposts
link.springer.com/article/10โฆ
Ashita Debnath, PharmD, BCIDP retweeted
๐ฅDOTS๐ฅ
The most anticipated RCT #ESCMIDGLOBAL2024 Dalbavancin is non-inferior to SOC by clinical efficacy for complicated SAB incl Rt sided IE
2 doses Dalba 1500 mg on days 1 & 8 or 4-8 wks of SOC(cefaz or naf:MSSA;vanc or dapto:MRSA)
DOOR at D70
Slides shared by @LordAlirezaF
Ashita Debnath, PharmD, BCIDP retweeted
pubmed.ncbi.nlm.nih.gov/3152โฆ #IDTwitter any experience using ertapenem thrice weekly after hemodialysis to treat ESBL enterobacterales infection for instance a Klebsiella Osteomyelitis? @BradSpellberg @DrToddLee @ABsteward @wwrighID @dralicehan @mmPharmD @JGPharmD @CynthiaNixon
Ashita Debnath, PharmD, BCIDP retweeted
Everyone who's treating MRSA Bacteremia should read this article now!
An excellent review by @VanceFowler5 et Al @CIDJournal
Persistent MRSA Bacteremia: Resetting the Clock for Optimal Management
๐Excellent figures ๐
@snap_trial
Thoughts ๐ค #IDTwitter
academic.oup.com/cid/articleโฆ
ALT Persistent MRSA bacteremia
Ashita Debnath, PharmD, BCIDP retweeted
In case you missed it--this one's big!!๐ฅ๐ฅ
in @JAMAInternalMed we found inappropriate diagnosis of #pneumonia to be common and abx treatment harmful. Similar parallels to ASB--> highest risk in older adults with dementia & altered mental status. jamanetwork.com/journals/jamโฆ
Ashita Debnath, PharmD, BCIDP retweeted
๐๏ธ๐ฅ #AJG
A non-inferiority trial comparing 2 days vs. 5 days of terlipressin and ceftriaxone in terms of 5-day rebleeding for patients with acute gastro-esophageal variceal hemorrhage #IDXposts
@BradSpellberg #Shorterisbetter?
journals.lww.com/ajg/abstracโฆ
Ashita Debnath, PharmD, BCIDP retweeted
๐๏ธโก๏ธ @AJHPOfficial
Cost evaluation of continuation of therapy with dalbavancin compared to standard-of-care antibiotics alone in hospitalized persons who inject drugs with severe gram-positive infections #IDXposts #PWID
academic.oup.com/ajhp/advancโฆ
Ashita Debnath, PharmD, BCIDP retweeted
๐๏ธ๐ฅ Systematic Review and Meta-Analysis @OFIDJournal
Investigating Non-Penicillin Therapeutic Strategies in Syphilis Treatment
Penicillin monotherapy did not outperform ceftriaxone, azithromycin, or doxycycline.
#IDXposts academic.oup.com/ofid/articlโฆ
Ashita Debnath, PharmD, BCIDP retweeted
๐๏ธ๐ฅThe largest real-world, multicenter study of dalbavancin use for Gram-positive BSI @NicholasRebold @IDpharmresearch and many @SIDPharm ๐s
Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection #IDXposts #DOTS
link.springer.com/article/10โฆ